Sorafenib 200mg

DRUG3 trials

Sponsors

Mina Alpha Limited, The University of Hong Kong, Sinocelltech Ltd.

Conditions

AMLFLT3-ITD MutationHepatocellular CarcinomaLiver Cancer

Phase 1

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer

Mina Alpha LimitedHepatocellular Carcinoma, Liver Cancer

Start: 2016-03-01End: 2025-07-31Updated: 2025-03-10

Phase 2

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

CompletedNCT03622541

The University of Hong KongAML, FLT3-ITD Mutation

Start: 2010-11-15End: 2020-03-01Updated: 2020-03-30

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Active, not recruitingNCT04560894

Sinocelltech Ltd.Hepatocellular Carcinoma

Start: 2020-11-11End: 2024-09-30Updated: 2024-02-01

Related Papers

The small activating RNA AW1-51 induces locus-specific demethylation and CEBPA protein early upregulation

Blood2025-11-03

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

2025-08-062 citations

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.

2025-03-315 citations

Small Activating RNA-Mediated Induction of <i>HBG</i> Via Liposome Delivery for <i>In Vivo</i> Treatment of Sickle Cell Disease and Beta-Thalassemia

Blood2024-11-051 citations

SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.

Journal of Clinical Oncology2024-06-0112 citations

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

Clinical Cancer Research2021-08-1883 citations

Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2020-05-203 citations

First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2020-02-013 citations

Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Journal of Clinical Oncology2018-05-206 citations

Abstract 1508: MTL-CEBPA activates the transcription factor CEBPalpha leading to inhibition of hepatocellular cancer growth

Cancer Research2017-07-01

First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Journal of Clinical Oncology2017-05-205 citations